Hhlr Advisors LTD. Has $660,000 Stock Holdings in Aligos Therapeutics, Inc. (NASDAQ:ALGS)

Hhlr Advisors LTD. lowered its stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS) by 97.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 76,247 shares of the company’s stock after selling 3,045,442 shares during the period. Hhlr Advisors LTD. owned approximately 2.38% of Aligos Therapeutics worth $660,000 as of its most recent filing with the SEC.

Separately, Acadian Asset Management LLC increased its holdings in Aligos Therapeutics by 26.1% in the 2nd quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock valued at $289,000 after buying an additional 171,490 shares during the period. 60.43% of the stock is owned by institutional investors.

Aligos Therapeutics Stock Performance

Shares of ALGS opened at $25.51 on Friday. Aligos Therapeutics, Inc. has a 52-week low of $6.76 and a 52-week high of $30.00. The firm has a market cap of $91.58 million, a price-to-earnings ratio of -1.92 and a beta of 2.11. The business’s fifty day moving average is $11.83 and its 200-day moving average is $12.67.

Aligos Therapeutics (NASDAQ:ALGS) last released its earnings results on Wednesday, November 6th. The company reported ($3.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92). Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. The business had revenue of $1.27 million during the quarter, compared to the consensus estimate of $1.00 million. During the same quarter in the prior year, the firm earned ($10.25) EPS. As a group, research analysts forecast that Aligos Therapeutics, Inc. will post -10.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $75.00 price target on shares of Aligos Therapeutics in a research report on Thursday, November 7th.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).